NewAmsterdam Pharma (NAMS) EBT Margin (2023 - 2025)
Historic EBT Margin for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to 20691.09%.
- NewAmsterdam Pharma's EBT Margin fell 206339000.0% to 20691.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 627.28%, marking a year-over-year decrease of 352400.0%. This contributed to the annual value of 530.25% for FY2024, which is 7253200.0% up from last year.
- According to the latest figures from Q3 2025, NewAmsterdam Pharma's EBT Margin is 20691.09%, which was down 206339000.0% from 90.7% recorded in Q2 2025.
- Over the past 5 years, NewAmsterdam Pharma's EBT Margin peaked at 57.19% during Q3 2024, and registered a low of 20691.09% during Q3 2025.
- In the last 3 years, NewAmsterdam Pharma's EBT Margin had a median value of 1602.62% in 2023 and averaged 3797.5%.
- Its EBT Margin has fluctuated over the past 5 years, first soared by 54386900bps in 2024, then tumbled by -206339000bps in 2025.
- Quarter analysis of 3 years shows NewAmsterdam Pharma's EBT Margin stood at 6160.4% in 2023, then surged by 88bps to 721.71% in 2024, then plummeted by -2767bps to 20691.09% in 2025.
- Its EBT Margin was 20691.09% in Q3 2025, compared to 90.7% in Q2 2025 and 1327.3% in Q1 2025.